Cathay Biotech (SHSE:688065) Short-Term Debt: ¥294 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688065 Cathay Biotech Inc SHSE:688065
93 GF Score
Price ¥44.00
GF Value ¥49.77
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cathay Biotech Short-Term Debt?

Cathay Biotech SHSE:688065 -2.81% 93 Short-Term Debt is ¥294 Mil as of Jun. 2026. GuruFocus rates SHSE:688065 with a GF Score™ of 93/100 and a GF Value™ of ¥49.77 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Cathay Biotech's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥294 Mil.

Cathay Biotech's quarterly Short-Term Debt increased from Dec. 2025 (¥301 Mil) to Mar. 2026 (¥762 Mil) but then declined from Mar. 2026 (¥762 Mil) to Jun. 2026 (¥294 Mil).

Cathay Biotech's annual Short-Term Debt increased from Dec. 2023 (¥746 Mil) to Dec. 2024 (¥1,247 Mil) but then declined from Dec. 2024 (¥1,247 Mil) to Dec. 2025 (¥301 Mil).

Cathay Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Cathay Biotech Short-Term Debt Related Terms

Cathay Biotech Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Cathay Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cathay Biotech Short-Term Debt Chart

Cathay Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 743.51 161.47 746.25 1,246.91 301.22

Cathay Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.39 71.75 301.22 761.51 294.04
SHSE:688065
93GF Score
Cathay Biotech Inc SHSE:688065
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥294 Mil mean?
Cathay Biotech (SHSE:688065) has a Short-Term Debt of ¥294 Mil as of Jun. 2026.
Is Cathay Biotech's Short-Term Debt too high?
Cathay Biotech's current Short-Term Debt is ¥294 Mil. Overall, Cathay Biotech has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cathay Biotech's Short-Term Debt compare to DOW?
Cathay Biotech's Short-Term Debt of ¥294 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Chemicals company?
A good Short-Term Debt depends on the Chemicals industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Cathay Biotech's current Short-Term Debt is ¥294 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cathay Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cathay Biotech (SHSE:688065) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥49.77, compared to a current price of ¥44.00 — trading 11.6% below its estimated fair value. The current Short-Term Debt is ¥294 Mil. Cathay Biotech's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Cathay Biotech (SHSE:688065), the current Short-Term Debt is ¥294 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cathay Biotech (SHSE:688065) Overvalued in 2026?

Based on GuruFocus' analysis, Cathay Biotech stock appears to be undervalued. The current stock price of ¥44.00 is trading 11.6% below its estimated GF Value™ of ¥49.77. GuruFocus considers Cathay Biotech to be Modestly Undervalued.

Key valuation signals for SHSE:688065:

  • Short-Term Debt: ¥294 Mil
  • GF Value™: ¥49.77 vs. price of ¥44.00 (11.6% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688065 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cathay Biotech Business Description

Address Oasis Ring Road, Building 11, Lane 396, Minhang District, Shanghai, CHN, 201114
Cathay Biotech Inc is engaged in research, development, production, and sales of new bio-based materials. The company owns the TERRYL brand, which focuses on bio-based polyamide fibers for textiles, and ECOPENT, which serves the engineering materials market.
93GF Score

Get the complete analysis for SHSE:688065

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥44.00
Price
¥49.77
GF Value